Clinical Trials Browser

Phase 1/2 × OTHER × capmatinib × Clear all

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT05243641 2025-06-11

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1/2 Terminated

10 enrolled 11 charts

Breast Neoplasms